Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axial Biotech Inc.

www.axialbiotech.com

Latest From Nanosys Inc.

BioDirection Inc.

BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injury. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.

BioDirection Inc.

BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injuries. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.

Medical Device

Medtronic: Doing Just What the Doctors Order

Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Medical Device Business Strategies

Can Nanotech Be a Game-Changer for In Vitro Diagnostics?

People have awakened to the opportunities in diagnostics. Molecular information offers the potential for increased test sensitivity, and reduced upfront sample prep using nanotechnology could provide the means for many gene- and protein-based diagnostic tests to transition out of the central lab. Nanotech may also enable the use of newly discovered or newly usable biomarkers. Finally, unlike the traditional point-of-care model, a new wave of nanotech-based instruments could bring testing even closer to the patient.
Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Axial Biotech Inc.
  • Senior Management
  • John M Climaco, Pres. & CEO
    Eric K Olson, EVP, Sales & Mktg.
    A. Stewart Campbell, PhD, VP, Early-Stage Dev.
  • Contact Info
  • Axial Biotech Inc.
    Phone: (801) 984-9100
    2749 E. Parley’s Way, Ste. 200
    Salt Lake City, UT 84109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register